RU2318518C2 - Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием - Google Patents

Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием Download PDF

Info

Publication number
RU2318518C2
RU2318518C2 RU2004129280/15A RU2004129280A RU2318518C2 RU 2318518 C2 RU2318518 C2 RU 2318518C2 RU 2004129280/15 A RU2004129280/15 A RU 2004129280/15A RU 2004129280 A RU2004129280 A RU 2004129280A RU 2318518 C2 RU2318518 C2 RU 2318518C2
Authority
RU
Russia
Prior art keywords
water
agent
pharmaceutical composition
cellulose ether
soluble cellulose
Prior art date
Application number
RU2004129280/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004129280A (ru
Inventor
Пол Ричард ДЖЕЛЛЕРТ
Майкл Дейвис ПАРКЕР
Марсел ДЕ-МАТАС
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2318518(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2004129280A publication Critical patent/RU2004129280A/ru
Application granted granted Critical
Publication of RU2318518C2 publication Critical patent/RU2318518C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2004129280/15A 2002-02-26 2003-02-24 Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием RU2318518C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0204392.5 2002-02-26
GB0212462.6 2002-05-30
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition
GB0213267.8 2002-06-11

Publications (2)

Publication Number Publication Date
RU2004129280A RU2004129280A (ru) 2005-06-10
RU2318518C2 true RU2318518C2 (ru) 2008-03-10

Family

ID=27767732

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004129280/15A RU2318518C2 (ru) 2002-02-26 2003-02-24 Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием

Country Status (29)

Country Link
US (2) US20050163835A1 (https=)
EP (1) EP1480679B1 (https=)
JP (1) JP4544863B2 (https=)
KR (2) KR20100090726A (https=)
CN (1) CN1326569C (https=)
AR (1) AR038848A1 (https=)
AT (1) ATE362771T1 (https=)
AU (1) AU2003208444B2 (https=)
BR (1) BRPI0307786B8 (https=)
CA (1) CA2476587C (https=)
CO (1) CO5601038A2 (https=)
CY (1) CY1108026T1 (https=)
DE (1) DE60313956T2 (https=)
DK (1) DK1480679T3 (https=)
ES (1) ES2286406T3 (https=)
IL (2) IL163642A0 (https=)
IS (1) IS2462B (https=)
MX (1) MXPA04008307A (https=)
MY (1) MY135609A (https=)
NO (1) NO328658B1 (https=)
NZ (1) NZ534513A (https=)
PL (1) PL208114B1 (https=)
PT (1) PT1480679E (https=)
RU (1) RU2318518C2 (https=)
SA (1) SA03240043B1 (https=)
TW (1) TWI271193B (https=)
UA (1) UA76325C2 (https=)
UY (1) UY27682A1 (https=)
WO (1) WO2003072139A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143074A3 (en) * 2009-06-08 2011-02-17 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342660T3 (es) 2002-02-26 2010-07-12 Astrazeneca Ab Nuevas formas cristalinas del compuesto anticancerigeno zd1839.
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
CN1972688B (zh) 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-苯胺基-喹唑啉-6-基-酰胺类化合物
PT1928409E (pt) * 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
KR20120038021A (ko) 2006-10-27 2012-04-20 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
KR20160083132A (ko) * 2007-06-06 2016-07-11 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
BRPI1015941A2 (pt) * 2009-07-02 2016-04-19 Wyeth Llc formulações de comprimido de 3-cianoquinolina e uso das mesmas.
SG10201500152UA (en) * 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
US8395552B2 (en) 2010-11-23 2013-03-12 Metamagnetics, Inc. Antenna module having reduced size, high gain, and increased power efficiency
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
AR092707A1 (es) 2012-09-28 2015-04-29 Takeda Pharmaceuticals Co Metodo de produccion de derivado de tienopirimidina
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
WO2016096999A1 (en) 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising gefifinib
TWI744224B (zh) * 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 固形製劑
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
JP6739289B2 (ja) * 2016-08-25 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬錠剤の製造方法
MA46361A (fr) 2016-09-30 2021-03-31 Myovant Sciences Gmbh Traitement du cancer de la prostate
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
GB2306885A (en) * 1995-11-08 1997-05-14 Reckitt & Colmann Prod Ltd Supersaturated pharmaceutical compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
EP0716597A1 (en) * 1993-08-30 1996-06-19 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP4713698B2 (ja) * 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
ES2342660T3 (es) * 2002-02-26 2010-07-12 Astrazeneca Ab Nuevas formas cristalinas del compuesto anticancerigeno zd1839.
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
GB2306885A (en) * 1995-11-08 1997-05-14 Reckitt & Colmann Prod Ltd Supersaturated pharmaceutical compositions

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143074A3 (en) * 2009-06-08 2011-02-17 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US9872861B2 (en) 2010-11-23 2018-01-23 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
TW200304379A (en) 2003-10-01
EP1480679B1 (en) 2007-05-23
CY1108026T1 (el) 2013-09-04
IL163642A (en) 2007-07-24
KR101002374B1 (ko) 2010-12-17
SA03240043B1 (ar) 2007-05-06
DE60313956T2 (de) 2008-05-15
NO328658B1 (no) 2010-04-19
CO5601038A2 (es) 2006-01-31
ATE362771T1 (de) 2007-06-15
TWI271193B (en) 2007-01-21
DE60313956D1 (de) 2007-07-05
US20090186890A1 (en) 2009-07-23
NZ534513A (en) 2007-04-27
NO20043866L (no) 2004-09-15
CN1326569C (zh) 2007-07-18
AU2003208444B2 (en) 2006-10-26
PL372215A1 (en) 2005-07-11
UA76325C2 (uk) 2006-07-17
AU2003208444A1 (en) 2003-09-09
MXPA04008307A (es) 2004-11-26
KR20100090726A (ko) 2010-08-16
PT1480679E (pt) 2007-07-18
JP4544863B2 (ja) 2010-09-15
DK1480679T3 (da) 2007-09-03
CA2476587C (en) 2010-05-04
HK1070585A1 (en) 2005-06-24
IS7420A (is) 2004-08-24
RU2004129280A (ru) 2005-06-10
IS2462B (is) 2008-11-15
BRPI0307786B1 (pt) 2018-03-13
US20050163835A1 (en) 2005-07-28
WO2003072139A1 (en) 2003-09-04
KR20040088524A (ko) 2004-10-16
IL163642A0 (en) 2005-12-18
MY135609A (en) 2008-05-30
CA2476587A1 (en) 2003-09-04
AR038848A1 (es) 2005-01-26
JP2005523293A (ja) 2005-08-04
PL208114B1 (pl) 2011-03-31
BRPI0307786B8 (pt) 2021-05-25
CN1638805A (zh) 2005-07-13
ES2286406T3 (es) 2007-12-01
BR0307786A (pt) 2004-12-07
UY27682A1 (es) 2003-10-31
EP1480679A1 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
RU2318518C2 (ru) Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием
US20250017930A1 (en) Pharmaceutical compositions comprising azd9291
US20070141141A1 (en) Pharmaceutical composition
ZA200406361B (en) Pharmaceutical formulation of iressa comprising a watersoluble cellulose derivative.
JP6077459B2 (ja) 固形製剤
JP2018020968A (ja) ゲフィチニブを有効成分とする医薬組成物
HK1070585B (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
HK1225655B (en) Pharmaceutical compositions comprising azd9291